Early intensive diabetes therapy preserves beta-cell function

July 6, 2012
Early intensive diabetes therapy preserves β-cell function
Early, intensive therapy for type 2 diabetes with either insulin plus metformin or triple oral therapy preserves β-cell function for at least 3.5 years, according to a study published in the July issue of Diabetes Care.

(HealthDay) -- Early, intensive therapy for type 2 diabetes with either insulin plus metformin or triple oral therapy preserves β-cell function for at least 3.5 years, according to a study published in the July issue of Diabetes Care.

Lindsay B. Harrison, M.D., of the University of Texas Southwestern Medical Center in Dallas, and colleagues conducted a randomized trial involving 58 patients with treatment-naive, newly diagnosed . Participants were treated for three months with and and were then randomly allocated to continue with insulin plus metformin or to receive triple oral therapy with metformin, glyburide, and pioglitazone. A mixed meal challenge test was used to assess β-cell function at randomization and six, 12, 18, 30, and 42 months.

After 3.5 years the researchers found that 83 percent of insulin plus metformin-treated patients and 72 percent of triple oral therapy patients completed the study, with good compliance noted in both groups. At 3.5 years after diagnosis, β-cell function was preserved between the groups, with no significant change from baseline or between-group difference (end of study hemoglobin A1c, 6.35 percent for insulin plus metformin versus 6.59 percent for triple oral therapy). In both groups there was an increase in weight, with no significant difference between the groups. Hypoglycemic episodes decreased over time for both groups and were not significantly different.

"Intensive insulin therapy at the time of diagnosis of type 2 followed by either an insulin-based regimen or multiple oral hypoglycemic agents preserves both glycemic control and β-cell function for at least 3.5 years with no significant difference in the adverse-effect profile," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Novo Nordisk, which funded the study.

Explore further: Study shows treating diabetes early, intensively is best strategy

More information: Abstract
Full Text

Related Stories

Study shows treating diabetes early, intensively is best strategy

June 28, 2012
Intensive early treatment of type 2 diabetes slows down progression of the disease by preserving the body's insulin-producing capacity, a UT Southwestern study has shown.

Patients with Type 2 diabetes may not benefit from oral medication as well as insulin

April 20, 2012
Patients suffering from type 2 diabetes may not benefit from taking both an oral glucose lowering drug (metformin) and insulin instead of insulin alone, a study published on bmj.com claims.

Researchers test a drug-exercise program designed to prevent type 2 diabetes

December 6, 2011
(Medical Xpress) -- Kinesiology researcher Barry Braun of the University of Massachusetts Amherst and colleagues recently reported unexpected results of a study suggesting that exercise and one of the most commonly prescribed ...

Dapagliflozin aids glycemic control in type 2 diabetes

March 20, 2012
(HealthDay) -- For patients with inadequately controlled type 2 diabetes, treatment with dapagliflozin is associated with improved glycemic control, stabilized insulin dosing, and weight reductions, according to research ...

Recommended for you

Diabetes pill might replace injection to control blood sugar

October 17, 2017
(HealthDay)— An injectable class of diabetes medication—called glucagon-like peptide-1 or GLP-1—might one day be available in pill form, research suggests.

Skimping on sleep may contribute to gestational diabetes

October 17, 2017
The amount of time spent sleeping in the United States has dropped significantly in the past twenty years with almost a quarter of women and 16 percent of men experiencing insufficient sleep. Now, a new study has found that ...

Artificial pancreas performs well in clinical trial

October 16, 2017
During more than 60,000 hours of combined use of a novel artificial pancreas system, participants in a 12-week, multi-site clinical trial showed significant improvements in two key measures of well-being in people living ...

Omega-6 fats may help prevent type 2 diabetes

October 11, 2017
The risk of developing type 2 diabetes could be significantly reduced by eating a diet rich in omega-6 polyunsaturated fats, a new study suggests.

Where there's type 1 diabetes, celiac disease may follow

October 10, 2017
(HealthDay)—Parents of young children with type 1 diabetes need to be on the lookout for symptoms of another autoimmune condition—celiac disease, new research suggests.

Type 1 diabetes and the microbiota—MAIT cells as biomarkers and new therapeutic targets

October 10, 2017
Together with colleagues from AP-HP Necker–Enfants Malades Hospital in Paris, scientists from the Cochin Institute (CNRS / INSERM / Paris Descartes University) have discovered that the onset of type 1 diabetes is preceded ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.